Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...

Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the two pivotal Phase 3 randomized, ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial ...

BENGALURU: Dermatologists in Bengaluru are reporting an increase in psoriasis cases during the ongoing winter season, with both new patients and those previousl ...

Study Links Mediterranean Diet to Lower Multiple Sclerosis Risk Levels Eating your way to brain health might be simpler than ...

Vanda Pharmaceuticals (VNDA) stock hit a two-year high on news it filed a FDA application for its psoriasis drug ...

Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Belgium: Johnson & Johnson has announced that the European Commission has extended the marketing authorisation for TREMFYA ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Extends Pediatric Psoriasis Study: What ...